RPG Life Sciences has soared 18% to Rs 72.45 after returning to profit in the fourth quarter ended March 31, 2013.
The pharmaceutical company has reported a net profit of Rs 7.40 crore in Q4FY13, as against net loss of Rs 5.69 crore during the corresponding quarter of previous fiscal. Net sales increased by 37% to 56.34 crore from Rs 41.23 crore during the recently concluded quarter.
“The investments made in upgradation of manufacturing facility, formulation business, during the year constraining the profitability,” says Ajit Singh Chouhan, managing director of the company.
Meanwhile, the board recommends dividend at 15% of face value of Rs 1.20 per share.
The stock opened at Rs 66.30 and hit a high of Rs 73.85 on NSE. A combined 18,261 shares have changed hands on the counter till 1004 hours on NSE and BSE.
The pharmaceutical company has reported a net profit of Rs 7.40 crore in Q4FY13, as against net loss of Rs 5.69 crore during the corresponding quarter of previous fiscal. Net sales increased by 37% to 56.34 crore from Rs 41.23 crore during the recently concluded quarter.
“The investments made in upgradation of manufacturing facility, formulation business, during the year constraining the profitability,” says Ajit Singh Chouhan, managing director of the company.
Meanwhile, the board recommends dividend at 15% of face value of Rs 1.20 per share.
The stock opened at Rs 66.30 and hit a high of Rs 73.85 on NSE. A combined 18,261 shares have changed hands on the counter till 1004 hours on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%